scholarly journals New heart failure therapy: The shape of things to come?

2003 ◽  
Vol 125 (3) ◽  
pp. S50-S52 ◽  
Author(s):  
Daniel Burkhoff
Keyword(s):  
Heart Failure ◽  
Heart Failure Therapy ◽  
To Come

scholarly journals New heart failure therapy: The shape of things to come?

2001 ◽  
Vol 122 (3) ◽  
pp. 421-423 ◽  
Author(s):  
Daniel Burkhoff
Keyword(s):  
Heart Failure ◽  
Heart Failure Therapy ◽  
To Come

409 The likely numbers to come: trends in hospitalisation for heart failure in the ‘sample’ town of trieste and its region

2003 ◽  
Vol 2 (1) ◽  
pp. 84
Author(s):  
D CHERSEVANI ◽  
A DILENARDA ◽  
P GOLIANI ◽  
M GRELLA ◽  
F BRUN ◽  
...  
Keyword(s):  
Heart Failure ◽  
Its Region ◽  
To Come

Destination therapy with magnetically levitated pumps – the next major widespread advance in heart failure therapy?

2013 ◽  
Vol 61 (S 01) ◽  
Author(s):  
C Heim ◽  
J Rösch ◽  
M Kondruweit ◽  
M Weyand ◽  
R Tandler
Keyword(s):  
Heart Failure ◽  
Destination Therapy ◽  
Heart Failure Therapy ◽  
Magnetically Levitated

Cardiac tamponade from anticoagulant-related spontaneous haemopericardium in a patient with ischaemic cardiomyopathy and heart failure

2020 ◽  
Vol 13 (12) ◽  
pp. e238047
Author(s):  
Alicia Lefas ◽  
Neil Bodagh ◽  
Jiliu Pan ◽  
Ali Vazir
Keyword(s):  
Heart Failure ◽  
Cardiac Tamponade ◽  
Ventricular Dysfunction ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Left Ventricular ◽  
Heart Failure Therapy ◽  
Severe Left Ventricular Dysfunction ◽  
Ischaemic Cardiomyopathy ◽  
Common Causes

We describe the case of an 86-year-old man with a background of severe left ventricular dysfunction and ischaemic cardiomyopathy who, having been optimised for heart failure therapy in hospital, unexpectedly deteriorated again with hypotension and progressive renal failure over the course of 2 days. Common causes of decompensation were ruled out and a bedside echocardiogram unexpectedly diagnosed new pericardial effusion with tamponade physiology. The patient underwent urgent pericardiocentesis and 890 mL of haemorrhagic fluid was drained. Common causes for haemopericardium were ruled out, and the spontaneous haemopericardium was thought to be related to introduction of rivaroxaban anticoagulation. The patient made a full recovery and was well 2 months following discharge. This case highlights the challenges of diagnosing cardiac tamponade in the presence of more common disorders that share similar non-specific clinical features. In addition, this case adds to growing evidence that therapy with direct oral anticoagulants can be complicated by spontaneous haemopericardium, especially when coadministered with other agents that affect clotting, renal dysfunction and cytochrome P3A5 inhibitors.

scholarly journals Cardiac Amyloidosis Therapy: A Systematic Review

2021 ◽  
Vol 11 (1) ◽  
pp. 10-17
Author(s):  
Franco Iodice ◽  
Marco Di Mauro ◽  
Marco Giuseppe Migliaccio ◽  
Angela Iannuzzi ◽  
Roberta Pacileo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Cardiac Amyloidosis ◽  
Restrictive Cardiomyopathy ◽  
Novel Therapies ◽  
Preserved Ejection Fraction ◽  
Cardiac Damage ◽  
Transthyretin Amyloidosis ◽  
To Come ◽  
Almost All

Heart involvement in Cardiac Amyloidosis (CA) results in a worsening of the prognosis in almost all patients with both light-chain (AL) and transthyretin amyloidosis (ATTR). The mainstream CA is a restrictive cardiomyopathy with hypertrophic phenotype at cardiac imaging that clinically leads to heart failure with preserved ejection fraction (HFpEF). An early diagnosis is essential to reduce cardiac damage and to improve the prognosis. Many therapies are available, but most of them have late benefits to cardiac function; for this reason, novel therapies are going to come soon.

Effect of Digoxin on Clinical Outcomes in Patients on Contemporary Heart Failure Therapy

2008 ◽  
Vol 14 (6) ◽  
pp. S100
Author(s):  
Amandeep S. Dhaliwal ◽  
Blaise Carabello ◽  
Audrius Bredikis ◽  
Gabriel Habib ◽  
Kumudha Ramasubbu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Outcomes ◽  
Heart Failure Therapy

The role of race in heart failure therapy

2002 ◽  
Vol 4 (3) ◽  
pp. 218-225 ◽  
Author(s):  
Clyde W. Yancy
Keyword(s):  
Heart Failure ◽  
Heart Failure Therapy

Pulmonary pressure, telemedicine, and heart failure therapy

The Lancet ◽  
2016 ◽  
Vol 387 (10017) ◽  
pp. 408-410 ◽  
Author(s):  
Nikolaos Dagres ◽  
Gerhard Hindricks
Keyword(s):  
Heart Failure ◽  
Heart Failure Therapy ◽  
Pulmonary Pressure

Heart Failure Therapy in 2016

2016 ◽  
Vol 51 (1) ◽  
pp. 79-82
Author(s):  
Douglas L. Jennings
Keyword(s):  
Heart Failure ◽  
Recent Literature ◽  
Residual Disease ◽  
Angiotensin Receptor ◽  
Heart Failure Therapy ◽  
Call To Action ◽  
Neprilysin Inhibitor ◽  
Drug Regimens ◽  
Contemporary Practice

Heart failure (HF) continues to afflict millions of Americans, resulting in substantial clinical and economic burden to our society. Recent literature has highlighted the role of 2 novel therapies (an angiotensin receptor blocker/neprilysin inhibitor and ivabradine) in further reducing residual disease in HF. Simultaneously, evidence has mounted suggesting that older therapies like digoxin are not effective in contemporary practice and, in fact, may be harmful. This editorial summarizes the most recently published articles pertaining to both new and old HF therapies and provides a call to action to pharmacists on how to shift patients toward effective drug regimens.

Sign in / Sign up

Export Citation Format

Share Document